ANTIANGINAL THERAPY IN PATIENTS WITH STABLE ANGINA

Download full text PDF
Issue: 
5
Year: 
2017

Professor L. Minushkina, MD Central State Medical Academy, Presidential Administration of the Russian Federation, Moscow

The treatment of stable angina involves the use of life expectancy-increasing drugs (antiaggregants, statins, angiotensin-converting enzyme inhibitors, and sartans), and antianginal medications. The first-line antianginal drugs prescribed for angina include β-adrenoblockers and calcium antagonists, the second-line medications are long-acting nitrates, ivabradine, nicorandil, trimetazidine, and ranolazine. The paper discusses the anti-ischemic efficacy of nicorandil and describes Russian and foreign trials investigating the drug. It gives data on the additional properties of nicorandil, which allow its use in the therapy of coronary heart disease.

Keywords: 
cardiology
coronary heart disease
angina pectoris
nicorandil
antianginal drugs



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Task Force Members. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology // Eur. Heart J. – 2013; 34 (38): 2949–3003.
  2. Ong P., Athanasiadis A., Sechtem U. Treatment of Angina Pectoris Associated with Coronary Microvascular Dysfunction // Cardiovasc. Drugs Ther. – 2016; 30 (4): 351–6. DOI: 10.1007/s10557-016-6676-z.
  3. Krumenacker M., Roland E. Clinical profile of nicorandil: an overview of its hemodynamic properties and therapeutic efficacy // J. Cardiovasc. Pharmacol. – 1992; 20 (Suppl. 3): 93–102.
  4. Frydman A., Chapelle P., Diekmann H. et al. Pharmacokinetics of nicorandil // Am. J. Cardiol. – 1989; 63 (21): 25J–33J.
  5. Karpov Ju.A., Kuharchuk V.V., Ljakishev A.A. i dr. Diagnostika i lechenie hronicheskoj ishemicheskoj bolezni serdtsa. Klinicheskie rekomendatsii // Kardiol. vestn. Bjul. ros. kardiol. nauchno-proizvodstvennogo kompleksa. – 2015; 3: 3–33.
  6. Voronina V.P., Martsevich S.Ju., Kutishenko N.P. i dr. Otsenka antiishemicheskogo i antianginal'nogo effektov nikorandila s pomosch'ju nagruzochnyh testov na tredmile v ramkah issledovanija KVAZAR // Ros. kardiol. zhurn. – 2017; 3 (143): 97–103.
  7. Martsevich S.Ju., Kutishenko N.P., Deev A.D. Sravnitel'naja otsenka antianginal'noj effektivnosti i bezopasnosti preparata nikorandil na fone bazisnoj terapii β-adrenoblokatorami u bol'nyh ishemicheskoj bolezn'ju serdtsa so stabil'noj stenokardiej // Kardiologija. – 2016; 56 (10): 30–4.
  8. Raftery E., Lahiri A., Hughes L. et al. A double-blind comparison of a beta-blocker and a potassium channel opener in exercise induced angina // Eur. Heart J. – 1993; 14 (Suppl. B): 35–9.
  9. Di Somma S., Liguori V., Petitto M. et al. A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris // Cardiovasc. Drugs Ther. – 1993; 7 (1): 119–23.
  10. Guermonprez J., Blin P., Peterlongo F. A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris // Eur. Heart J. – 1993; 14 (Suppl. B): 30–4.
  11. Ulvenstam G., Diderholm E., Frithz G. et al. Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study // J. Cardiovasc. Pharmacol. – 1992; 20 (Suppl. 3): 67–73.
  12. Sani H., Eshraghi A., Nezafati M. et al. Nicorandil Versus Nitroglycerin for Symptomatic Relief of Angina in Patients With Slow Coronary Flow Phenomenon: A Randomized Clinical Trial // J. Cardiovasc. Pharmacol. Ther. – 2015; 20 (4): 401–6. DOI: 10.1177/1074248415571457.
  13. Zhu W., Shan Y., Guo J. Double-blind, multicenter, active-controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pectoris in China // Circ J. – 2007; 71 (6): 826–83.
  14. Rezvanova Ju.A., Adamchik A.S. Otsenka antiishemicheskoj i kardioprotektivnoj effektivnosti nikorandila u patsientov so stabil'noj stenokardiej // Kardiologija. – 2015; 8: 21–5.
  15. Sizova Zh.M., Zaharova V.L., Kozlova N.V. i dr. Vlijanie aktivatora kalievyh kanalov nikorandila na kachestvo zhizni bol'nyh ishemicheskoj bolezn'ju serdtsa so stabil'noj stenokardiej naprjazhenija // Kardiologija. – 2016; 6: 5–11.
  16. Bulahova E.Ju., Korennova O.Ju., Kondrasheva M.N. i dr. Klinicheskie preimuschestva terapii nikorandilom v sravnenii s izosorbid-5-mononitratom u bol'nyh IBS // Serdtse. – 2013; 12 (2): 83–7.
  17. Chen J., Lee W., Hsu N. Effects of short-term treatment of nicorandil on exercise-induced myocardial ischemia and abnormal cardiac autonomic activity in microvascular angina // Am. J. Cardiol. – 1997; 80 (1): 32–8.
  18. Lee K., Kim S., Lim H. Effectiveness of intravenous administration of nicorandil in a patient with variant angina refractory to continuous intravenous nitroglycerin // Int. J. Cardiol. – 2007; 120 (1): 9–12.
  19. Hanai Y., Mita M., Hishinuma S. et al. Systematic review on the short-term efficacy and safety of nicorandil for stable angina pectoris in comparison with those of β-blockers, nitrates and calcium antagonists // Yakugaku Zasshi. – 2010; 130 (11): 1549–63.
  20. Fihn S., Gardin J., Abrams J. et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons // J. Am. Coll. Cardiol. – 2012; 60 (24): 44–164. DOI: 10.1016/j.jacc.2012.07.013.
  21. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial // Lancet. – 2002; 359 (9314): 1269–75.
  22. IONA Study Group. Determinants of coronary events in patients with stable angina: results from the impact of nicorandil in angina study // Am. Heart J. – 2005; 150 (4): 689.
  23. Natsional'nye klinicheskie rekomendatsii. VNOK. Effektivnost' i bezopasnost' lekarstvennoj terapii pri pervichnoj i vtorichnoj profilaktike SSZ // Ratsional'naja farmakoterapija v kardiologii. – 2011; 7 (5): 2–72.
  24. Sakai K., Yamagata T., Teragawa H. et al. Nicorandil-induced preconditioning as evidenced by troponin T measurements after coronary angioplasty in patients with stable angina pectoris // Jpn. Heart J. – 2002; 43 (5): 443–53.
  25. Sakata Y., Nakatani D., Shimizu M. Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction // J. Cardiol. – 2012; 59 (1): 14–21.
  26. Izumiya Y., Kojima S., Kojima S. et al. Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris // Atherosclerosis. – 2011; 214 (2): 415–21. DOI: 10.1016/j.atherosclerosis.2010.11.032.
  27. Markham A., Plosker G., Goa K. Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardio-protective effects // Drugs. – 2000; 60: 955–74.
  28. Sekiya M., Sato M., Funada J. et al. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis // J. Cardiovasc. Pharmacol. – 2005; 46 (1): 63–7.
  29. Kasama S., Toyama T., Sumino H. et al. Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction // J. Nucl. Med. – 2007; 48 (10): 1676–82.
  30. Kasama S., Toyama T., Hatori T. et al. Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy // Am. Heart J. – 2005; 150 (3): 477.e1–477.e8.
  31. Eguchi Y., Takahari Y., Higashijima N. et al. Nicorandil Attenuates FeCl3-Induced Thrombus Formation Through the Inhibition of Reactive Oxygen Species Production // Circ. J. – 2009; 73 (3): 554–61.
  32. Patel D., Purcell H., Fox K. On behalf of the CESAR 2 investigation. Cardioprotection by opening of the KATP channel in unstable angina // Eur. Heart J. – 1999; 20: 51–7.
  33. Wei J., Watanabe Y., Takeuchi K. et al. Nicorandil stimulates a Na+/Ca2+ exchanger by activating guanylate cyclase in guinea pig cardiac myocytes // Pflugers Arch. – 2016; 468 (4): 693–703.